In this Healio Video Perspective from Glaucoma 360 New Horizons Forum, Thurein Htoo, MS, MBA, CEO and co-founder of Qlaris Bio, discusses study results for QLS-111.
QLS-111 is an ATP-sensitive potassium channel modulator that selectively targets episcleral venous pressure (EVP) in glaucoma.
“With this novel mechanism targeting EVP and an excellent safety profile, the potential of QLS-111 extends beyond primary open-angle glaucoma alone,” he said. “QLS-111 may provide a substantial benefit as an IOP-lowering agent for patients where EVP has limited maximum pharmacotherapy.”